{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:52:36Z","timestamp":1790700756732,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["21ZR1414600"],"award-info":[{"award-number":["21ZR1414600"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Pujiang Program","award":["2019PJD007"],"award-info":[{"award-number":["2019PJD007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Receptor-interacting protein kinase 2 (RIPK2, also known as RIP2) was reported to be associated with bacterial infections as well as inflammatory responses. However, the role of RIPK2 in prognosis and immunotherapy response is yet to be elucidated in human pan-cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we investigated the expression, gene alteration landscape and prognostic value of RIPK2 in 33 cancers through various databases including Ualcan, cBioportal and Gene Expression Profiling Interactive Analysis 2 (GEPIA2). Then, the correlation between RIPK2 and immune infiltration, immune score, stromal score, and ESTIMATE score was investigated in the Cancer Genome Atlas (TCGA) and tumor immune estimation resource (TIMER) databases. Independent cohorts were utilized to explore the role of RIPK2 in tumor immunotherapy response. Furthermore, Gene set enrichment analysis (GSEA) was conducted to explore the mechanisms by which RIPK2 regulates immune therapy resistance. Single-cell RNA-seq datasets were used to analyze the expression level of RIPK2 on different immune cells. Moreover, CellMiner database was used to explore the relationship between RIPK2 expression with drug response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Compared with normal tissue, tumor tissue had a higher expression level of RIPK2 in various cancers. Survival analysis showed that high expression of RIPK2 associated with poor prognosis in numerous cancers. RIPK2 was found to promote a series of immune cell infiltration and B cells, macrophages, and neutrophils were significantly positively correlated with the expression of RIPK2. Moreover, RIPK2 affected immune score, stromal score and ESTIMATE score for a wide range of cancers. In the vast majority of 33 cancers, gene co-expression analysis showed that RIPK2 was positively correlated with the expression of immune checkpoint markers, such as PDCD1 (PD-1), CD274 (PD-L1), CTLA4 and TIGIT. RIPK2 aggravated cytotoxic T lymphocyte (CTL) dysfunction and related to the poor efficacy of immune checkpoint blockade in skin cutaneous melanoma (SKCM) and kidney renal clear cell carcinoma (KIRC). High expression of RIPK2 promoted innate immunotherapy resistance and adaptive immunotherapy resistance through IL-6\/JAK\/STAT3 signaling, interferon-gamma response, and interferon-alpha response pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results confirmed that RIPK2 could serve as a prognostic biomarker and promoted immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-022-00475-8","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:02:58Z","timestamp":1651647778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction"],"prefix":"10.1186","volume":"28","author":[{"given":"Junquan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"475_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.gde.2013.11.014","volume":"24","author":"LB Alexandrov","year":"2014","unstructured":"Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev. 2014;24:52\u201360. https:\/\/doi.org\/10.1016\/j.gde.2013.11.014.","journal-title":"Curr Opin Genet Dev"},{"key":"475_CR2","doi-asserted-by":"publisher","unstructured":"Bartha A, Gyorffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021; 22(5). https:\/\/doi.org\/10.3390\/ijms22052622.","DOI":"10.3390\/ijms22052622"},{"issue":"1","key":"475_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH, de Reynies A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5.","journal-title":"Genome Biol"},{"issue":"6","key":"475_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540\u201354 e1512. https:\/\/doi.org\/10.1016\/j.cell.2016.11.022.","journal-title":"Cell"},{"issue":"6","key":"475_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","volume":"15","author":"MF Berger","year":"2018","unstructured":"Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018;15(6):353\u201365. https:\/\/doi.org\/10.1038\/s41571-018-0002-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"475_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"475_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095.","journal-title":"Cancer Discov"},{"issue":"11","key":"475_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759\u201371. https:\/\/doi.org\/10.1038\/nrc3611.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"475_CR9","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159\u201367. https:\/\/doi.org\/10.1182\/blood-2018-11-844548.","journal-title":"Blood"},{"issue":"9","key":"475_CR10","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","volume":"19","author":"S He","year":"2018","unstructured":"He S, Wang X. RIP kinases as modulators of inflammation and immunity. Nat Immunol. 2018;19(9):912\u201322. https:\/\/doi.org\/10.1038\/s41590-018-0188-x.","journal-title":"Nat Immunol"},{"issue":"6","key":"475_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345\u201359. https:\/\/doi.org\/10.1038\/s41568-021-00347-z.","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"475_CR12","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3962.","journal-title":"Cancer Res"},{"issue":"5","key":"475_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41571-020-00459-9","volume":"18","author":"J Hou","year":"2021","unstructured":"Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261\u201379. https:\/\/doi.org\/10.1038\/s41571-020-00459-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"475_CR14","doi-asserted-by":"publisher","unstructured":"Hrdinka M, Schlicher L, Dai B, Pinkas DM, Bufton JC, Picaud S, Ward JA, Rogers C, Suebsuwong C, Nikhar S, Cuny GD, Huber KV, Filippakopoulos P, Bullock AN, Degterev A, Gyrd-Hansen M. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. EMBO J. 2018; 37(17). https:\/\/doi.org\/10.15252\/embj.201899372.","DOI":"10.15252\/embj.201899372"},{"issue":"1","key":"475_CR15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-017-9726-5","volume":"37","author":"D Huang","year":"2018","unstructured":"Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, Xia D, Xu E, Lai M, Wu Y, Zhang H. Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37(1):173\u201387. https:\/\/doi.org\/10.1007\/s10555-017-9726-5.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"475_CR16","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1.","journal-title":"Nat Med"},{"issue":"4","key":"475_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8.","journal-title":"Nat Rev Clin Oncol"},{"key":"475_CR18","doi-asserted-by":"publisher","first-page":"8537381","DOI":"10.1155\/2020\/8537381","volume":"2020","author":"X Li","year":"2020","unstructured":"Li X, Li Z, Zhu H, Yu X. Autophagy regulatory genes MET and RIPK2 play a prognostic role in pancreatic ductal adenocarcinoma: a bioinformatic analysis based on GEO and TCGA. Biomed Res Int. 2020;2020:8537381. https:\/\/doi.org\/10.1155\/2020\/8537381.","journal-title":"Biomed Res Int"},{"issue":"7","key":"475_CR19","doi-asserted-by":"publisher","first-page":"10450","DOI":"10.18632\/aging.202808","volume":"13","author":"D Li","year":"2021","unstructured":"Li D, Tang L, Liu B, Xu S, Jin M, Bo W. RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma. Aging. 2021;13(7):10450\u201367. https:\/\/doi.org\/10.18632\/aging.202808.","journal-title":"Aging"},{"key":"475_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.biopha.2017.08.003","volume":"95","author":"X Liu","year":"2017","unstructured":"Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017;95:55\u201361. https:\/\/doi.org\/10.1016\/j.biopha.2017.08.003.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"475_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/eji.201040827","volume":"41","author":"JG Magalhaes","year":"2011","unstructured":"Magalhaes JG, Lee J, Geddes K, Rubino S, Philpott DJ, Girardin SE. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol. 2011;41(5):1445\u201355. https:\/\/doi.org\/10.1002\/eji.201040827.","journal-title":"Eur J Immunol"},{"issue":"27","key":"475_CR22","doi-asserted-by":"publisher","first-page":"16968","DOI":"10.1074\/jbc.273.27.16968","volume":"273","author":"JV McCarthy","year":"1998","unstructured":"McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-\u03baB-activating and cell death-inducing kinase. J Biol Chem. 1998;273(27):16968\u201375. https:\/\/doi.org\/10.1074\/jbc.273.27.16968.","journal-title":"J Biol Chem"},{"issue":"14","key":"475_CR23","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72(14):3499\u2013511. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1370.","journal-title":"Cancer Res"},{"issue":"4","key":"475_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"2","key":"475_CR25","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/bcr3629","volume":"16","author":"SM Singel","year":"2014","unstructured":"Singel SM, Batten K, Cornelius C, Jia G, Fasciani G, Barron SL, Wright WE, Shay JW. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res. 2014;16(2):R28. https:\/\/doi.org\/10.1186\/bcr3629.","journal-title":"Breast Cancer Res"},{"issue":"200","key":"475_CR26","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. https:\/\/doi.org\/10.1126\/scitranslmed.3006504.","journal-title":"Sci Transl Med"},{"issue":"D1","key":"475_CR27","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, Shi X, Wang B, Li Z, Ren P, Sun L, Yan Y, Zhang P, Zhang F, Li T, Wang C. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420\u201330. https:\/\/doi.org\/10.1093\/nar\/gkaa1020.","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"475_CR28","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360. https:\/\/doi.org\/10.1093\/nar\/gkz430.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"475_CR29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"key":"475_CR30","doi-asserted-by":"publisher","first-page":"627464","DOI":"10.3389\/fgene.2021.627464","volume":"12","author":"Q Yang","year":"2021","unstructured":"Yang Q, Tian S, Liu Z, Dong W. Knockdown of RIPK2 inhibits proliferation and migration, and induces apoptosis via the NF-kappaB signaling pathway in gastric cancer. Front Genet. 2021;12:627464. https:\/\/doi.org\/10.3389\/fgene.2021.627464.","journal-title":"Front Genet"},{"key":"475_CR31","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"issue":"1","key":"475_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-020-01028-4","volume":"14","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Hu L, Tang W, Li D, Ma L, Liu H, Zhang S, Zhang X, Dong L, Shen X, Chen S, Xue R, Zhang S. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. J Hematol Oncol. 2021;14(1):9. https:\/\/doi.org\/10.1186\/s13045-020-01028-4.","journal-title":"J Hematol Oncol"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00475-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-022-00475-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-022-00475-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:21:45Z","timestamp":1651648905000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-022-00475-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1186\/s10020-022-00475-8","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"14 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}